Rhythm expects to achieve the following near-term milestones: Begin enrolling the first patients with congenital HO in a 34-week substudy of setmelanotide being conducted under the protocol for its global Phase 3 trial in the first quarter of 2025; Begin enrolling the first patients with Prader-Willi syndrome in a 26-week, open-label Phase 2 trial evaluating setmelanotide in the first quarter of 2025; Begin enrolling patients with acquired HO in Part C of the Phase 1 trial evaluating the weekly, MC4R agonist RM-718 in the first quarter of 2025; Announce top-line data in the Phase 3 trial evaluating setmelanotide in acquired HO in the second quarter of 2025; Announce topline data from the Phase 2 trial of bivamelagon in acquired HO in the second half of 2025; and Announce top-line data in the Phase 3 EMANATE trial evaluating setmelanotide in genetically caused MC4R pathway diseases in the first half of 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Analyst Recommends Buy Rating for Rhythm Pharmaceuticals Due to Setmelanotide’s Potential in Hypothalamic Obesity Market
- Optimistic Outlook for Rhythm Pharmaceuticals: Imcivree’s Promise in Treating Hypothalamic Obesity
- Is RYTM a Buy, Before Earnings?
- Buy Recommendation for Rhythm Pharmaceuticals: Promising Potential of Imcivree in Obesity Treatment
- Rhythm Pharmaceuticals: Promising Weight Loss Breakthroughs and Strategic Advancements Justify Buy Rating